FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200403780> ?p ?o ?g. }

• W4200403780 abstract "Abstract Aims The incidence of atrial fibrillation (AF) increases with age. The risk of stroke is increased 4- to 5-fold in old patients with AF. In the Framingham Study, 23.5% of strokes in patients aged 80 and older were attributable to AF. Advanced age is also associated with a progressive increase in the risk of major bleeding in subjects ≥85 years, particularly if treated by oral anticoagulants (OAC). Only 20% of patients &gt;75 years were included in randomized controlled trials (RCTs) involving OACs in AF, due to the high risk of falls and bleeding, especially intracranial haemorrhage (ICH). The management of anticoagulation in the very elderly represents a challenging issue because they are at high thromboembolic risk, and also at high haemorrhagic risk. The aim of our study was to describe the use and tolerability of rivaroxaban in very old patients with heart failure with reduced ejection fraction. The average age of enrolled patients is 76.0 ± 8.4 years with a significant prevalence of the elderly (16.0% with age ≥85 years with a slight male prevalence). Methods We analysed retrospective data from 50 patients from June 2016 to June 2018 and taking rivaroxaban 20 mg. The average age of enrolled patients was 76 ± 8.2 years and 40% were females. The inclusion criteria were patients with at least one episode of documented AF of any duration in the preceding 12 months. The average CHA2DS2-VASc of these subjects is 3.2 ± 1.4, while the haemorrhagic risk expressed by the HAS-BLED appears more contained (2.7 ± 1.1). The risk profile of these patients was complex as documented by an older age, by a CHA2DS2-VASc higher and by the prevalence of comorbidities such as heart failure, valvular disease, peripheral vasculopathy and diabetes mellitus. Follow-up, characterized by clinical examination and blood analysis, was performed at 3, 6, and 12 months. The AF patients were followed for the effectiveness outcome of thromboembolism (ischaemic stroke and/or systemic embolism) and bleeding outcomes (composite of major bleeding, gastrointestinal bleeding, and intracranial Haemorrhage), as well as bleeding requiring hospitalization. A secondary safety endpoint was total minor bleedings. Standard two-dimensional transthoracic echocardiographic examination was performed. Left ventricular end-diastolic volume, end-systolic volume, and ejection fraction (LVEF) were measured using the modified Simpson’s rule from the apical view. Results During follow-up, we observed no major bleedings, strokes, or cardiovascular deaths. Only two minor haemorrhages (one epistaxis and one haematuria, none of which required blood transfusion or hospital admission) observed with no differences observed in LVEF or left atrial dimension at echocardiography, body mass index, and the thrombotic and haemorrhagic risk profile. Conclusions Such data confirm that the new oral anticoagulants, and in particular rivaroxaban, are considered safe even in the most population frail and above all elderly, allowing for enlargement the use of anticoagulant therapy. Results are expected of long-term follow-up to confirm the benefits of that therapeutic choice." @default.
• W4200403780 created "2021-12-31" @default.
• W4200403780 creator A5019123445 @default.
• W4200403780 creator A5033695289 @default.
• W4200403780 creator A5062699447 @default.
• W4200403780 date "2021-12-01" @default.
• W4200403780 modified "2023-09-25" @default.
• W4200403780 title "156 Rivaroxaban in very elderly patients with atrial fibrillation" @default.
• W4200403780 doi "https://doi.org/10.1093/eurheartj/suab131.006" @default.
• W4200403780 hasPublicationYear "2021" @default.
• W4200403780 type Work @default.
• W4200403780 citedByCount "0" @default.
• W4200403780 crossrefType "journal-article" @default.
• W4200403780 hasAuthorship W4200403780A5019123445 @default.
• W4200403780 hasAuthorship W4200403780A5033695289 @default.
• W4200403780 hasAuthorship W4200403780A5062699447 @default.
• W4200403780 hasBestOaLocation W42004037801 @default.
• W4200403780 hasConcept C111815664 @default.
• W4200403780 hasConcept C11783203 @default.
• W4200403780 hasConcept C120665830 @default.
• W4200403780 hasConcept C121332964 @default.
• W4200403780 hasConcept C126322002 @default.
• W4200403780 hasConcept C127413603 @default.
• W4200403780 hasConcept C141071460 @default.
• W4200403780 hasConcept C164705383 @default.
• W4200403780 hasConcept C168563851 @default.
• W4200403780 hasConcept C187212893 @default.
• W4200403780 hasConcept C197934379 @default.
• W4200403780 hasConcept C2776301958 @default.
• W4200403780 hasConcept C2778198053 @default.
• W4200403780 hasConcept C2778375690 @default.
• W4200403780 hasConcept C2778661090 @default.
• W4200403780 hasConcept C2779134260 @default.
• W4200403780 hasConcept C2779161974 @default.
• W4200403780 hasConcept C2780645631 @default.
• W4200403780 hasConcept C61511704 @default.
• W4200403780 hasConcept C71924100 @default.
• W4200403780 hasConcept C78085059 @default.
• W4200403780 hasConcept C78519656 @default.
• W4200403780 hasConceptScore W4200403780C111815664 @default.
• W4200403780 hasConceptScore W4200403780C11783203 @default.
• W4200403780 hasConceptScore W4200403780C120665830 @default.
• W4200403780 hasConceptScore W4200403780C121332964 @default.
• W4200403780 hasConceptScore W4200403780C126322002 @default.
• W4200403780 hasConceptScore W4200403780C127413603 @default.
• W4200403780 hasConceptScore W4200403780C141071460 @default.
• W4200403780 hasConceptScore W4200403780C164705383 @default.
• W4200403780 hasConceptScore W4200403780C168563851 @default.
• W4200403780 hasConceptScore W4200403780C187212893 @default.
• W4200403780 hasConceptScore W4200403780C197934379 @default.
• W4200403780 hasConceptScore W4200403780C2776301958 @default.
• W4200403780 hasConceptScore W4200403780C2778198053 @default.
• W4200403780 hasConceptScore W4200403780C2778375690 @default.
• W4200403780 hasConceptScore W4200403780C2778661090 @default.
• W4200403780 hasConceptScore W4200403780C2779134260 @default.
• W4200403780 hasConceptScore W4200403780C2779161974 @default.
• W4200403780 hasConceptScore W4200403780C2780645631 @default.
• W4200403780 hasConceptScore W4200403780C61511704 @default.
• W4200403780 hasConceptScore W4200403780C71924100 @default.
• W4200403780 hasConceptScore W4200403780C78085059 @default.
• W4200403780 hasConceptScore W4200403780C78519656 @default.
• W4200403780 hasIssue "Supplement_G" @default.
• W4200403780 hasLocation W42004037801 @default.
• W4200403780 hasOpenAccess W4200403780 @default.
• W4200403780 hasPrimaryLocation W42004037801 @default.
• W4200403780 hasRelatedWork W2045126858 @default.
• W4200403780 hasRelatedWork W2067654556 @default.
• W4200403780 hasRelatedWork W2094027763 @default.
• W4200403780 hasRelatedWork W2101093423 @default.
• W4200403780 hasRelatedWork W2144048294 @default.
• W4200403780 hasRelatedWork W2397154677 @default.
• W4200403780 hasRelatedWork W2888986290 @default.
• W4200403780 hasRelatedWork W2920404400 @default.
• W4200403780 hasRelatedWork W2952625328 @default.
• W4200403780 hasRelatedWork W3142220971 @default.
• W4200403780 hasVolume "23" @default.
• W4200403780 isParatext "false" @default.
• W4200403780 isRetracted "false" @default.
• W4200403780 workType "article" @default.